Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 13/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 13/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 13/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 13/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 13/20 | 0.47 |
| ▸ | LMNA | P02545 | 7/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 7/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.46 |
| ▸ | USP2 | O75604 | 5/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.46 |
| ▸ | APLNR | P35414 | 1/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 6/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17048617 | 0.84 | APLNR (0.50) | NPC1RAB9APKMTSHRCYP1A2 | |
| SCHEMBL352828 | 0.84 | APLNR (0.50) | NPC1RAB9APKMTSHRCYP1A2 | |
| SCHEMBL14921907 | 0.80 | APLNR (0.54) | NPC1RAB9APKMTSHRCYP1A2 | |
| SCHEMBL30585984 | 0.79 | APLNR (0.52) | NPC1RAB9APKMTSHRCYP1A2 | |
| SCHEMBL21640422 | 0.79 | APLNR (0.52) | NPC1RAB9APKMTSHRCYP1A2 | |
| SCHEMBL4861129 | 0.77 | CYP1A2 (0.67) | NPC1RAB9APKMTSHRCYP1A2 | |
| SCHEMBL4959821 | 0.77 | APLNR (0.42) | NPC1RAB9APKMTSHRCYP1A2 | |
| SCHEMBL13717864 | 0.73 | DYRK1A (0.49) | NPC1RAB9ALMNAHSD17B10SMN1; SMN2 | |
| SCHEMBL21640504 | 0.73 | APLNR (0.46) | NPC1RAB9APKMTSHRCYP1A2 | |
| SCHEMBL30585654 | 0.73 | APLNR (0.46) | NPC1RAB9APKMTSHRCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236078-B2 | Heterocyclic inhibitors of the sodium channel | DeGiacomo, Mark G. (US) | 2022-02-01 | — | — | US | disclosed |
| US-11236078-B2 | Heterocyclic inhibitors of the sodium channel | DeGiacomo, Mark G. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20170145003-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | DeGiacomo, Mark G. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170145003-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | DeGiacomo, Mark G. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170145003-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | DeGiacomo, Mark G. (US) | 2017-05-25 | — | — | US | disclosed |
| WO-2015130957-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | Zalicus Pharmaceuticals, Ltd. (US) | 2015-09-03 | — | — | WO | disclosed |
| WO-2015130957-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | Zalicus Pharmaceuticals, Ltd. (US) | 2015-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145003-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | SCN1B, SCN1A, CACNA1S | NPC1 667/4885RAB9A 794/4885PKM 3999/4885 |
| US-11236078-B2 | Heterocyclic inhibitors of the sodium channel | SCN1B, TRPM6, SCN1A | NPC1 934/4885RAB9A 853/4885PKM 3901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.